Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 5c

August 1, 2019 7:33 AM

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.47), $0.05 worse than the analyst estimate of ($0.42). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found